Index - P/E - EPS (ttm) - Insider Own 38.63% Shs Outstand 103.04M Perf Week -
Market Cap 3.04B Forward P/E - EPS next Y - Insider Trans 15.14% Shs Float 63.23M Perf Month -
Income - PEG - EPS next Q - Inst Own 1.80% Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh -0.44 P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh 0.73 P/C 40.46 EPS next 5Y - ROE - 52W Range 25.06 - 30.02 Perf YTD 11.43%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -1.63% Beta -
Dividend TTM - Quick Ratio 3.81 Sales past 5Y 0.00% Gross Margin - 52W Low 17.84% ATR (14) 2.70
Dividend Ex-Date - Current Ratio 3.81 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility - -
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 1.32 Prev Close 29.25
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 1.72M Price 29.53
SMA20 4.65% SMA50 4.65% SMA200 4.65% Trades
Volume 2,259,929 Change 0.96%
Feb-05-25 04:01PM
Jan-30-25 08:13PM
06:53PM
02:57PM
Metsera is a clinical-stage biopharmaceutical company that focuses on creating innovative therapies for obesity and metabolic conditions. The company advances a range of oral and injectable treatment options while integrating proprietary health technology tools for personalized care.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burow Kristina Director Feb 03 '25 Buy 18.00 2,222,222 39,999,996 18,503,128 Feb 03 07:15 PM BERNS PAUL L Director Feb 03 '25 Buy 18.00 789,998 14,219,964 8,313,680 Feb 03 07:04 PM ARCH Venture Partners XII, LLC 10% Owner Feb 03 '25 Buy 18.00 2,222,222 39,999,996 18,503,128 Feb 03 07:01 PM
Index RUT P/E - EPS (ttm) -2.75 Insider Own 36.44% Shs Outstand 22.25M Perf Week -3.28%
Market Cap 52.63M Forward P/E - EPS next Y -3.31 Insider Trans 0.00% Shs Float 14.17M Perf Month -12.59%
Income -61.06M PEG - EPS next Q -0.76 Inst Own 50.90% Short Float 2.50% Perf Quarter -18.90%
Sales 0.00M P/S - EPS this Y 83.91% Inst Trans -4.59% Short Ratio 3.55 Perf Half Y -24.36%
Book/sh 7.42 P/B 0.32 EPS next Y 49.45% ROA -38.30% Short Interest 0.35M Perf Year -
Cash/sh 7.49 P/C 0.31 EPS next 5Y - ROE -249.02% 52W Range 2.15 - 15.24 Perf YTD -18.62%
Dividend Est. - P/FCF - EPS past 5Y - ROI -36.99% 52W High -84.51% Beta -
Dividend TTM - Quick Ratio 17.03 Sales past 5Y 0.00% Gross Margin - 52W Low 9.81% ATR (14) 0.22
Dividend Ex-Date - Current Ratio 17.03 EPS Y/Y TTM - Oper. Margin - RSI (14) 45.59 Volatility 8.59% 9.07%
Employees 72 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.67 Target Price 16.33
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q -25.24% Payout - Rel Volume 0.26 Prev Close 2.50
Sales Surprise - EPS Surprise 1.00% Sales Q/Q - Earnings Nov 07 AMC Avg Volume 99.83K Price 2.36
SMA20 -2.44% SMA50 -8.36% SMA200 -47.53% Trades
Volume 25,758 Change -5.60%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-24 Downgrade Guggenheim
Buy → Neutral
Apr-22-24 Initiated Piper Sandler
Overweight
$20
Apr-22-24 Initiated Leerink Partners
Outperform
$25
Apr-22-24 Initiated Guggenheim
Buy
$24
Feb-03-25 10:00AM
Dec-12-24 04:01PM
(GlobeNewswire) -12.72%
-16.61%
Nov-25-24 07:00AM
Nov-07-24 04:01PM
Nov-05-24 07:00AM
08:00AM
Loading…
Oct-14-24 08:00AM
Sep-11-24 07:00AM
Aug-13-24 04:28AM
03:32AM
Aug-12-24 10:53PM
04:01PM
Jun-05-24 07:00AM
May-13-24 02:53PM
07:00AM
May-06-24 08:00AM
10:05AM
Loading…
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Burow Kristina Director Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM CRANDELL KEITH 10% Owner Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM ARCH Venture Fund IX, L.P. 10% Owner Apr 02 '24 Buy 16.00 200,000 3,200,000 1,181,766 Apr 04 04:30 PM RA CAPITAL MANAGEMENT, L.P. 10% Owner Apr 02 '24 Buy 16.00 312,500 5,000,000 1,884,787 Apr 04 04:15 PM
Index RUT P/E - EPS (ttm) -1.85 Insider Own 65.85% Shs Outstand 160.48M Perf Week 1.56%
Market Cap 315.05M Forward P/E - EPS next Y -1.61 Insider Trans -0.20% Shs Float 55.17M Perf Month -21.37%
Income -293.70M PEG - EPS next Q -0.44 Inst Own 29.59% Short Float 19.99% Perf Quarter -83.35%
Sales 0.00M P/S - EPS this Y 55.94% Inst Trans 6.23% Short Ratio 3.63 Perf Half Y -83.74%
Book/sh 2.00 P/B 0.98 EPS next Y -0.85% ROA -65.46% Short Interest 11.03M Perf Year -87.15%
Cash/sh 2.12 P/C 0.92 EPS next 5Y 25.35% ROE -70.48% 52W Range 1.81 - 21.00 Perf YTD -81.60%
Dividend Est. - P/FCF - EPS past 5Y - ROI -91.57% 52W High -90.71% Beta 2.41
Dividend TTM - Quick Ratio 10.98 Sales past 5Y 0.00% Gross Margin - 52W Low 7.73% ATR (14) 0.38
Dividend Ex-Date - Current Ratio 10.98 EPS Y/Y TTM -80.83% Oper. Margin - RSI (14) 22.69 Volatility 5.43% 8.37%
Employees 124 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.44 Target Price 14.99
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -30.90% Payout - Rel Volume 0.25 Prev Close 1.94
Sales Surprise - EPS Surprise -15.24% Sales Q/Q - Earnings Nov 12 BMO Avg Volume 3.03M Price 1.95
SMA20 -6.18% SMA50 -69.57% SMA200 -80.71% Trades
Volume 773,682 Change 0.52%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-02-25 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$29 → $4
Nov-05-24 Downgrade JP Morgan
Overweight → Neutral
$18 → $15
Oct-01-24 Initiated H.C. Wainwright
Buy
$30
Jul-22-24 Initiated Needham
Buy
$23
Jul-08-24 Initiated Mizuho
Outperform
$20
Dec-12-23 Initiated Deutsche Bank
Hold
$13
Oct-10-23 Initiated William Blair
Outperform
$26
Oct-10-23 Initiated Stifel
Buy
$26
Oct-10-23 Initiated RBC Capital Mkts
Outperform
$24
Oct-10-23 Initiated JP Morgan
Overweight
$21
Oct-10-23 Initiated Guggenheim
Buy
$22
Oct-10-23 Initiated BofA Securities
Buy
$18
Show Previous Ratings
Jan-04-25 08:00AM
Jan-03-25 07:20AM
Jan-02-25 05:07PM
04:22PM
(Investor's Business Daily)
01:28PM
01:07PM
Loading…
01:07PM
(Pharmaceutical Technology)
12:00PM
10:47AM
09:59AM
09:54AM
08:30AM
07:00AM
Nov-19-24 08:53AM
Nov-12-24 07:00AM
Nov-06-24 07:00AM
07:00AM
Loading…
Oct-29-24 07:00AM
Aug-14-24 07:00AM
Aug-06-24 01:54PM
07:00AM
Jul-01-24 01:00AM
Jun-20-24 07:00AM
May-14-24 08:52AM
07:00AM
May-07-24 01:54PM
10:20AM
07:00AM
May-06-24 07:00AM
Apr-16-24 11:28AM
Apr-15-24 04:20PM
(Investor's Business Daily) -17.48%
12:17PM
08:45AM
Loading…
08:45AM
07:47AM
06:36AM
06:30AM
Mar-13-24 07:00AM
Mar-07-24 02:52PM
07:00AM
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
Sep-28-23 07:54PM
(InvestorPlace) +11.84%
+6.73%
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fust Matthew K Director Oct 18 '24 Option Exercise 5.29 14,049 74,309 34,149 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Option Exercise 6.81 7,739 52,730 27,839 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Sale 17.03 14,049 239,319 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Sale 17.01 7,739 131,643 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Proposed Sale 17.03 14,049 239,319 Oct 18 04:01 PM Fust Matthew K Director Oct 17 '24 Proposed Sale 17.01 7,739 131,643 Oct 17 04:26 PM Lenz Robert A. Head of R&D Oct 10 '24 Sale 15.09 8,260 124,603 314,706 Oct 11 04:10 PM Lenz Robert A. Head of R&D Oct 09 '24 Sale 15.01 5,563 83,507 322,966 Oct 11 04:10 PM Lenz Robert A. Officer Oct 10 '24 Proposed Sale 15.09 8,260 124,603 Oct 10 04:30 PM Lenz Robert A. Officer Oct 09 '24 Proposed Sale 15.01 5,563 83,507 Oct 09 04:10 PM Lenz Robert A. Head of R&D Sep 17 '24 Sale 11.81 30,788 363,736 339,205 Sep 19 04:35 PM Lenz Robert A. Head of R&D Sep 18 '24 Sale 12.09 10,676 129,091 328,529 Sep 19 04:35 PM Lenz Robert A. Officer Sep 18 '24 Proposed Sale 12.09 10,676 129,091 Sep 18 04:27 PM Lenz Robert A. Officer Sep 17 '24 Proposed Sale 11.81 30,788 363,734 Sep 17 04:37 PM Lenz Robert A. Head of R&D Sep 12 '24 Sale 11.43 32,948 376,665 369,993 Sep 16 04:05 PM Lenz Robert A. Officer Sep 12 '24 Proposed Sale 11.43 32,948 376,665 Sep 12 05:18 PM Pinto Joshua Chief Financial Officer Aug 27 '24 Sale 11.39 15,693 178,806 138,965 Aug 27 05:58 PM Pinto Joshua Chief Financial Officer Aug 26 '24 Sale 11.78 31,642 372,588 154,658 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 22 '24 Sale 11.63 28,496 331,468 210,469 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 23 '24 Sale 11.59 24,169 280,005 186,300 Aug 26 06:17 PM Pinto Joshua Officer Aug 22 '24 Proposed Sale 11.90 100,000 1,190,000 Aug 22 09:48 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
